文献速递产科母胎医学

胎盘生长因子指导小于胎龄儿管理:随机对照可行性研究

Placental Growth Factor Led Management of the Small for Gestational Age Fetus: Randomised Controlled Feasibility Study.
PubMed 文献 · BJOG · 2025-12-12

本研究旨在评估一项随机试验的可行性,该试验探讨对疑似晚发型早产和足月小于胎龄儿(SGA)使用血管生成生物标志物指导分娩时机。研究纳入32+0至37+6周的孕妇,按3:1随机分配至生物标志物指导组或标准护理组,主要结局为招募率和依从性。结果显示招募率为60.1%(95%CI 52%-69%),未发现显著不良事件或新生儿结局差异,但可行性尚不确定。

要点

  • 疑似SGA孕妇32+0至37+6周招募可行性研究,招募率60.1%。
  • 生物标志物指导组根据sFlt-1/PlGF比值决定分娩时机。
  • 未发现显著不良事件或新生儿结局差异,可行性尚不确定。

核心结论

  • 临床、定性及经济学结果支持使用sFlt-1/PlGF优化32+0周后SGA管理的可接受性,但可行性尚不确定。

研究设计与样本

  • 混合方法研究,包括随机可行性试验、访谈、问卷和经济学分析,在英国两家三级产科医院进行。
  • 纳入疑似SGA孕妇,孕周32+0至37+6周,按3:1随机分配至生物标志物指导组或标准护理组。

主要发现

  • 128名受邀女性中78名被招募,招募率为60.1%(95%CI 52%-69%)。
  • 参与者、伴侣和临床医生认为研究可接受,但在参与和实施中遇到挑战。
  • 未发现显著不良事件或新生儿结局差异,卫生经济学数据收集可行。

关键数值与推荐

  • 生物标志物指导组:sFlt-1/PlGF比值正常(<38 pg/mL)则分娩推迟至40周,异常(≥38 pg/mL)则从37周起考虑分娩。

临床怎么用

  • sFlt-1/PlGF可用于优化32+0周后SGA管理,但需进一步研究确认可行性。

局限性

  • 可行性研究,样本量小,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the feasibility of a trial investigating the optimal timing for the birth of women with a suspected late preterm and term SGA baby using either angiogenic biomarker-led care or standard care. DESIGN: A mixed methods study including a randomised feasibility trial, interviews, questionnaires and economic analysis. SETTING: Two tertiary maternity hospitals in the UK. POPULATION: Women with suspected SGA pregnancies between 32+0 weeks gestation and 37+6 weeks gestation. METHODS: Women were randomised in a 3:1 ratio to biomarker-led care versus standard care. Biomarker tests were either revealed, with birth delayed until 40 weeks if normal (sFlt-1/PlGF < 38 pg/mL) and considered from 37 weeks if abnormal (sFlt-1/PlGF ≥ 38 pg/mL), or concealed alongside standard care. MAIN OUTCOME MEASURES: Primary outcome was the feasibility of the study measured through the recruitment rate and adherence. Secondary outcomes were the qualitative, proof-of-concept and economic analyses. RESULTS: Out of 128 women invited to participate 78 women were recruited giving a recruitment rate of 60.1% (95% confidence interval 52%-69%). Sixty-seven of the 78 women consented to randomisation. Sixteen parents and 12 clinicians were interviewed. Fourty parents completed a questionnaire. Participants, partners and clinicians viewed the study as acceptable but experienced challenges in participation and delivering the study. There were no significant adverse events or differences in neonatal outcomes. Collection of health economics data was feasible. CONCLUSIONS: The clinical, qualitative and economic results support the acceptability of utilising sFlt-1/PlGF to refine SGA management after 32+0 weeks but the feasibility is less certain.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Bullough S, Dower M, Jackson R, et al. Placental Growth Factor Led Management of the Small for Gestational Age Fetus: Randomised Controlled Feasibility Study. BJOG. 2025. PMID: 41388623. doi:10.1111/1471-0528.70106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。